Objective: An impervious mortality rate in oral cancer (OC) to a certain extent explains the exigencies of precise biomarkers. Therefore, the study was intended to identify OC candidate biomarkers using samples of healthy normal tissues (N=335), adjacent normal tissues (N=93) and OC tissues (N=533) from online microarray data.
Methods: Differentially expressed genes (DEGs) were recognised through GeneSpring software (Fold change >4.0 and 'p' value.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190349 | PMC |
| http://dx.doi.org/10.31557/APJCP.2021.22.2.371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First study on the efficiency of Tc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma.
Ann Nucl Med
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Objective: To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent Tc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.
Methods: A retrospective study was conducted on 23 patients with OSCC who underwent Tc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.
Oral microbiota as a biomarker for predicting the risk of malignancy in indeterminate pulmonary nodules: a prospective multicenter study.
Int J Surg
December 2024
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China.
Background: Determining the benign or malignant status of indeterminate pulmonary nodules (IPN) with intermediate malignancy risk is a significant clinical challenge. Oral microbiota-lung cancer interactions have qualified oral microbiota as a promising non-invasive predictive biomarker in IPN.
Materials And Methods: Prospectively collected saliva, throat swabs, and tongue coating samples from 1040 IPN patients and 70 healthy controls across three hospitals.
Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiO Nanoparticles: A Dual-Action Strategy for Enhanced Radiotherapy and Immunomodulation in Oral Cancer Treatment.
Nanomaterials (Basel)
December 2024
Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Oral squamous-cell carcinoma (OSCC) poses significant treatment challenges due to its high recurrence rates and the limitations of current therapies. Titanium dioxide (TiO) nanoparticles are promising radiosensitizers, while bacterial outer membrane vesicles (OMVs) are known for their immunomodulatory properties. This study investigates the potential of OMV-encapsulated TiO nanoparticles (TiO@OMV) to combine these effects for improved OSCC treatment.
View Article and Find Full Text PDFExtract and Its Active Metabolite α-Cyperone Alleviates Paclitaxel-Induced Neuropathic Pain via the Modulation of the Norepinephrine Pathway.
Metabolites
December 2024
Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Republic of Korea.
Background: Paclitaxel is a widely used anticancer drug for ovarian, lung, breast, and stomach cancers; however, its clinical use is often limited by the side effects of peripheral neuropathy. This study evaluated the effects of () extract and its active metabolite, α-cyperone, on paclitaxel-induced neuropathic pain.
Methods: The oral administration of extract at doses of 500 mg/kg and intraperitoneal administration of α-cyperone at doses of 480 and 800 μg/kg prevented both the development of cold and mechanical pain.
The Clinical Characteristics of a Stage II Colorectal Cancer T4 Tumor: A Ten-Year Single-Center Research Report.
Curr Oncol
December 2024
Taichung Veterans General Hospital, Taichung 407219, Taiwan.
Aim: The tumor staging of colorectal cancer (CRC) plays a significant role in both treatment and prognosis, impacting surgical planning and adjuvant therapy decisions. Currently, the staging of CRC is based on the TNM system developed by the American Joint Committee on Cancer. Prior studies have suggested that survival rates and recurrent rates of T4a tumors appear to be worse than that of T4b tumors, although there is currently no consensus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!